Business
Result of AGM
Result of AGM.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\nOndine Biomedical Inc.\n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\nResult of AGM\nOndine Biomedical (AIM: OBI) announces that at its Annual General Meeting held on 24 May 2023 all resolutions were duly passed.\n \n\n\n\nOndine Biomedical Inc. \n\n\n \n\n\n\n\nAngelika Vance, Corporate Communications\n\n\n+001 (1) 604 838 2702\n\n\n\n\n \n\n\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser and Joint Broker)\n\n\n \n\n\n\n\nAubrey Powell, Asha Chotai, Sam Butcher \n\n\n+44 (0)20 7496 3000\n\n\n\n\n \n\n\n \n\n\n\n\nRBC Capital Markets (Joint Broker)\n\n\n \n\n\n\n\nRupert Walford, Kathryn Deegan\n\n\n+44 (0) 20 7653 4000\n\n\n\n\n \n\n\n \n\n\n\n\nVane Percy & Roberts (Media Contact)\n\n\n \n\n\n\n\nSimon Vane Percy, Amanda Bernard\n\n\n+44 (0) 77 1000 5910\n\n\n\n \nAbout Ondine Biomedical Inc.\nOndine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.\n \n\n","length":4608,"tagName":"div"}]